期刊
FUTURE ONCOLOGY
卷 5, 期 9, 页码 1335-1348出版社
FUTURE MEDICINE LTD
DOI: 10.2217/FON.09.112
关键词
angiogenesis; breast; cervix; glyomas; lung; multiple myeloma; ovarian; pazopanib; renal; sarcomas; thyroid; tyrosine kinase; VEGF
类别
Pazopanib, a tyrosine kinase inhibitor targeted to angiogenesis, has been tested in preclinical and clinical trials and has shown promising activity against a variety of solid tumors, such as renal cancer, all of which are related to the angiogenic pathway, It has a safety profile related to this mechanism of action. Diarrhea, hypertension, hair depigmentation and nausea are the most common side effects. Pazopanib is currently under evaluation as monotherapy and in combination with some potentially synergistic agents of proven activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据